1 Min Read
April 27 (Reuters) - U.S. biotechnology company Celgene Corp reported a 17.5 percent jump in quarterly net income on Thursday, helped by demand for its flagship multiple myeloma drug Revlimid.
The company's net income rose to $941 million, or $1.16 per share, in the first quarter ended March 31, from $801 million, or 99 cents per share, a year earlier.
Total revenue rose to $2.96 billion from $2.51 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)